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Magnesium for Treatment of Acute Lacunar
Stroke Syndromes
Further Analysis of the IMAGES Trial
Stella Aslanyan, PhD; Christopher J. Weir, PhD; Keith W. Muir, MD, FRCP;
Kennedy R. Lees, MD, FRCP; for the IMAGES Study Investigators
Background and Purpose—A prespecified interaction analysis of the neutral Intravenous Magnesium Efficacy in Stroke
(IMAGES) trial revealed significant benefit from magnesium (Mg) in patients with noncortical stroke. Post hoc analysis
indicated that this effect was seen in lacunar clinical syndromes (LACS), interaction P0.005. We have now examined
whether this interaction could be explained by confounding baseline factors.
Methods—LACS was defined on the basis of neurological signs and did not include imaging. We investigated the
interaction between baseline variables and Mg treatment on global outcome. We used logistic-regression models to test
whether the Mg-LACS interaction remained significant after adjusting for stratification variables, sex, a novel stroke
severity score, and baseline variables that had an interaction with treatment (P0.1).
Results—The Mg (n383) and placebo (n382) groups of LACS patients were well matched on baseline factors. In
addition to LACS, we found an interaction between beneficial Mg treatment effect and younger age (P0.003), higher
baseline diastolic blood pressure (P0.02), higher mean blood pressure (P0.02), and absence of ischemic heart disease
(P0.07). Even so, the adjusted Mg-LACS interaction remained significant (odds ratio [OR] 0.57; 95% CI, 0.39 to 0.83;
P0.003). In the LACS subgroup, Mg improved Barthel Index 95 (OR 0.73; 95% CI, 0.55 to 0.98), modified Rankin
Scale 1 (OR 0.67; 95% CI, 0.50 to 0.91), and global outcome (OR 0.70; 95% CI, 0.53 to 0.92) but not Barthel Index
60 or mortality.
Conclusions—The positive treatment effect of Mg in LACS cannot be ascribed to general issues of severity, time to
treatment, blood pressure, or other baseline factors; equally, this finding may be due to chance. A large trial of Mg
treatment in LACS appears justified. (Stroke. 2007;38:1269-1273.)
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Most clinical trials for acute stroke either have groupedlacunar stroke syndromes alongside cortical syndromes
or have even excluded them. The Intravenous Magnesium
Efficacy in Stroke (IMAGES) randomized clinical trial1
included all stroke syndromes but incorporated in the proto-
col a preplanned subgroup analysis of cortical versus non-
cortical stroke. The final results of IMAGES showed that
randomized treatment with MgSO4 did not reduce the global
outcome rate (primary end point) compared with placebo.1
The planned interaction analysis revealed a significant
benefit in the predefined subgroup of patients with noncorti-
cal stroke. This was an unexpected but biologically plausible
beneficial effect of MgSO4. Mg, in comparison with several
other putative neuroprotectants, had previously been shown
to confer white matter protection.2 Post hoc analysis of
IMAGES data indicated that the effect in subcortical stroke
was greatest in patients with lacunar clinical syndrome
(LACS) (odds ratio [OR] 0.70; 95% CI, 0.53 to 0.92) and
confirmed a significant interaction between treatment and
LACS (P0.005).1 IMAGES also reported a significant
interaction between treatment effect and baseline mean ar-
terial blood pressure (MABP) (P0.02), with benefit in
patients with a higher-than-median MABP in a post hoc
analysis. Because Mg is known to lower BP, the effect of Mg
on LACS may alternatively be mediated by reducing BP
acutely.
In this further analysis, we aimed to confirm or refute the
unexpected but biologically plausible findings of IMAGES.
In particular, we investigated whether the interaction between
Mg treatment and LACS is related to confounding factors that
may have spuriously generated the apparent benefit in LACS
patients. We examined the descriptive statistics, Mg treat-
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ment effect on outcome, and potential interactions within the
subset of patients with LACS.
Subjects and Methods
IMAGES was an academically organized and sponsored, random-
ized, multicenter, international trial of acute stroke treatment with
MgSO4. It lasted 6 years from 1997 and was approved by research
ethics committees of the participating institutions. From 100
centers, IMAGES randomized 2589 patients, and the efficacy dataset
included 2386 patients. Treatment commenced within 12 hours of
stroke onset and was continued for 24 hours. Global outcome was
assessed at day 907 by a combination of the Barthel Index (BI)3
and modified Rankin Score (mRS),4 with favorable outcome defined
as BI 90 or mRS 2.
Stroke was categorized into subtypes based on neurological signs
collected at baseline. Investigators documented the presence of
motor deficits for each of face, arm, and leg; dysphasia; hemianopia;
brainstem signs; inattention/neglect; and hemisensory loss. The
protocol did not require pretreatment confirmation of the clinical
diagnosis by imaging, which was permitted up to day 7. Known
hemorrhagic strokes were excluded only when imaging studies had
shown this before randomization. The method used for LACS
classification in the IMAGES trial was chosen to be simple but
robust. All patients with both arm and leg weakness but without
cortical features (sensory inattention or dysphasia), hemianopia,
ataxia, or brainstem features were regarded as having had lacunar
stroke. Patients with monoparesis were assumed to have a cortical
syndrome.1 This method allows inclusion of only 2 of the classic
lacunar syndromes (pure motor stroke and sensorimotor stroke) and
does not strictly correspond to the Oxfordshire Community Stroke
Project5 classification system.
Conventional neurological stroke severity scores were not as-
sessed in IMAGES. An IMAGES stroke scale (ISS) was generated
from the baseline neurological signs.6 ISS ranges from 0 to 16; for
the lacunar stroke syndrome subset, the median score was 5 (range 3
to 9, interquartile range 4 to 5).
Statistical Analysis
The interaction between baseline variables and Mg treatment on
global outcome was tested after adjusting for stratification variables
(age group, side of symptoms, time from onset to randomization, and
stroke type) in the IMAGES efficacy dataset with use of a bivariate
logistic-regression model. The efficacy of Mg on global outcome
(adjusted for stratification variables) was separately assessed for
each subgroup of baseline variables that had an interaction proba-
bility value 0.1. We tested whether the interaction between Mg
treatment and LACS identified in post hoc analysis of the original
IMAGES article1 remained statistically significant after further
adjustment for sex, ISS, and variables that had shown a significant
interaction with treatment.
The remaining analysis was conducted solely on the LACS
subgroup. Baseline factors were described for each treatment group
to confirm that randomization had achieved good balance for case
mix. BI and mRS outcomes at 3 months were tabulated by treatment
group. In the LACS subset, after adjustment for stratification
variables, we identified interactions between baseline variables and
treatment on global outcome that were significant at P0.1. LACS
patients were stratified by variables that showed an interaction with
treatment, and the treatment effects were presented within each
stratum.
Results
Efficacy Dataset (n2386)
In addition to an interaction of Mg treatment with LACS in
predicting global outcome, there was an interaction between
Mg treatment and each of age, baseline diastolic BP (DBP),
baseline MABP (all stratified by median; 71 years,
83 mm Hg, and 108 mm Hg, respectively), and history of
ischemic heart disease (Figure 1). However, a statistically
significant positive treatment effect was identified only in
younger patients (P0.02; Figure 1). Other baseline variables
(sex, ISS score, baseline systolic BP, pulse pressure, predom-
inant side of weakness, time from stroke to infusion, history
of hypertension, previous stroke, previous transient ischemic
attack, atrial fibrillation, valvular heart disease, diabetes
mellitus, smoking in the past year, hyperlipidemia, and
middle cerebral artery perforator infarction confirmed on
brain imaging) failed to show any interaction with treatment.
After adjustment for the stratification variables, there was
a significant interaction between Mg and LACS for all
outcome measures apart from mortality (Table 1). After
addition of sex, ISS score, and the variables that had an
interaction with Mg treatment identified in Figure 1, the
interaction between Mg and LACS remained significant
(Table 1).
LACS Subgroup (n765)
There were 765 (32.1%) patients with LACS in the efficacy
dataset. The Mg group (n383) included 31 (8.1%) patients
with primary hemorrhage, and the placebo group (n382)
included 37 (9.7%) patients with primary hemorrhage. Pri-
mary hemorrhage included cases of primary intracerebral
hemorrhage, subarachnoid hemorrhage, and subdural hemor-
rhage confirmed by imaging. The case mix was similar
Figure 1. Efficacy dataset: Mg efficacy on global outcome (adjusted for stratification variables) separately within each subgroup of
baseline variables that have an interaction with Mg treatment (P0.1). *ORs were adjusted for the stratification variables (age group,
side of symptoms, and time from onset to treatment).
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between treatment groups (Table 2), although there was a
tendency toward lower age and systolic BP and higher rates
of diabetes in the Mg treatment group.
Figure 2 presents the distribution of outcome measures by
treatment groups and adjusted ORs for dichotomous outcome
measures. There was a beneficial treatment effect of Mg on
BI 95, mRS 1, and global outcome. There was a nonsig-
nificant tendency toward a beneficial effect of Mg on BI60.
There was no significant effect on mortality rate. When the
full distribution of mRS at 3 months was analyzed with the
Cochran-Mantel-Haenszel test (P0.0052 univariate and
P0.0223 after correction for stratification variables and
ISS), Mg still had a positive treatment effect. The adjusted
proportional OR was 0.72 (95% CI, 0.56 to 0.93).
In the subset of patients with LACS, interactions were
identified between Mg and both age (P0.09) and baseline
DBP (P0.03) for prediction of global outcome. Median
values for age (70 years) and DBP (86 mm Hg) were used for
stratification. After adjustment for stratification variables, Mg
was efficacious in patients of median age or younger (OR
0.57; 95% CI, 0.39 to 0.83) and in patients with a greater-
than-median baseline DBP (OR 0.52; 95% CI, 0.35 to 0.76).
When these 2 interactions were included in the logistic-
regression models, Mg had a tendency to improve all out-
come measures, but the effect was not statistically significant.
The CIs for ORs were wide and substantially overlapped the
CIs of Mg treatment effect adjusted for stratification variables
only (Figure 2). There was no statistically significant differ-
ence between treatment groups in the rate of serious adverse
events reported during the first 48 hours after trial entry
(supplemental Table I, available online at http://stroke.
ahajournals.org).
Discussion
The main finding of our analyses is that, even after adjust-
ment for baseline factors such as sex, stroke severity, and
variables that showed an independent interaction with Mg
treatment or were used for stratification, Mg treatment im-
proved the chances of a good functional outcome in patients
with LACS. This indicates that the effect evident in the
IMAGES subgroup analysis was not due to a confounding
effect of other prerandomization factors and provides support
for the possibility that Mg treatment improves outcome in
LACS. Stroke patients who were younger, had a higher
MABP or DBP, and did not have a history of ischemic heart
disease especially benefited from Mg treatment.
The treatment groups in the LACS subset were well
balanced. The treatment effect observed in LACS was con-
sistent for both functional outcome measures, BI and mRS,
but was absent for mortality; however, this is expected,
because early mortality is rare in LACS patients, and neither
the main IMAGES trial nor the subgroup had adequate power
to detect an effect on mortality. Clearly, selection of an
appropriate outcome measure for a lacunar stroke trial will be
important and may not necessarily be the same as that used
for an unselected population. It may be desirable to explore
the potential of using novel patient-specific end points.7
After additional adjustment for Mg-age and Mg-DBP in-
teractions, the effect of Mg had only a tendency toward
benefit in the LACS subgroup, but the CIs were wide. In the
larger dataset of all stroke patients, wherein statistical power
was greater, the interaction between Mg and LACS remained
significant, even after additional adjustment for interactions
between Mg and age, DBP, MABP, and absence of a history
of ischemic heart disease.
A benefit from Mg in acute white matter infarction is
biologically plausible2; however, most animal-model studies
support the effect of Mg on neuronal cell bodies. The
tolerance of white matter to ischemia may be greater than for
gray matter, so the time window for its protection may be
TABLE 1. Efficacy Dataset: Interaction Between Mg Treatment
and LACS
Outcome Measure
Model I* (n2386) Model II† (n2276)
OR (95% CI) P Value OR (95% CI) P Value
Global outcome 0.60 (0.42–0.85) 0.0046 0.57 (0.39–0.83) 0.0032
BI 95 0.61 (0.42–0.89) 0.0103 0.56 (0.38–0.84) 0.0048
BI 60 0.63 (0.41–0.99) 0.0441 0.61 (0.38–0.98) 0.0420
mRS 1 0.60 (0.41–0.88) 0.0098 0.58 (0.38–0.87) 0.0094
Mortality 0.85 (0.43–1.68) 0.6311 0.94 (0.46–1.92) 0.8609
*Adjusted for stratification variables only.
†Full model included age, baseline DBP, baseline MABP (all categorized by
quartile), sex, ISS score, and history of ischemic heart disease, in addition to
stratification variables.
TABLE 2. LACS Subgroup: Demography and Baseline
Characteristics by Treatment Group
Baseline Factors Placebo (n382) Mg (n383)
Age, y* 68.7 (12.6) 67.0 (12.7)
Baseline systolic BP, mm Hg* 164.3 (28.2) 160.3 (29.3)
Baseline DBP, mm Hg* 87.4 (17.3) 86.9 (17.7)
Baseline MABP, mm Hg* 113.0 (18.8) 111.4 (19.9)
Baseline pulse pressure, mm Hg* 76.9 (22.3) 73.5 (21.0)
Heart rate, bpm* 77.8 (16.1) 77.1 (14.1)
ISS† 5.0 (4.0, 5.0) 5.0 (4.0, 5.0)
Time from stroke to infusion, h† 7.7 (5.5, 10.0) 7.7 (5.6, 10.5)
Sex, women, n (%) 168 (44.0) 162 (42.3)
Principal lesion compatible with acute
stroke? n (%)
193 (54.5) 189 (53.1)
If yes, is it in middle cerebral artery
perforator territory? n (%)
95 (49.2) 91 (48.1)
Medical history, n (%)
Hypertension 215 (56.3) 213 (55.6)
Previous stroke 66 (17.3) 60 (15.7)
Previous transient ischemic attack 56 (14.7) 50 (13.1)
Ischemic heart disease 79 (20.7) 79 (20.6)
Atrial fibrillation 36 (9.4) 48 (12.5)
Valvular heart disease 11 (2.9) 10 (2.6)
Diabetes mellitus 62 (16.2) 82 (21.4)
Smoker in past year 96 (25.1) 110 (28.7)
Hyperlipidemia 49 (12.8) 53 (13.8)
*Mean and (SD).
†Median and (interquartile range).
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longer. Outcome assessment in animal models of stroke is
predominantly based on histological lesion volume, which is
largely determined by cortical infarction (and by extension,
assumed to involve neuronal cell bodies). White matter
constitutes a smaller proportion of the rodent brain, and
quantitative measurement techniques for axonal injury are
less clearly established, so evaluation of therapeutic effects
on white matter has been difficult. Because most other
possible neuroprotectant agents act at receptors or intracellu-
lar targets that are predominantly or exclusively present in
neurons, cortical lesion volume is a relevant marker of effect,
and exclusion of lacunar strokes from “proof-of-principle”
clinical trials is a logical mechanism for enriching the trial
population.8 Although we should remain cautious until our
findings can be confirmed independently in a prospective,
randomized trial, this study suggests that lacunar stroke
patients may represent a relevant and practical target popu-
lation for agents with biological activity in white matter.
The pathophysiology of lacunar syndromes is poorly un-
derstood, but fluctuation in clinical status over time is a
common observation that may be the basis for a beneficial
effect being unrelated to the time from stroke to infusion.
This again raises the possibility of a vasoactive mechanism in
addition to, or instead of, a neuroprotectant one. Regardless
of mechanism, the IMAGES data indicate no justification for
exclusion of late-presenting patients from a future trial, at
least up to 12 hours. Whether the treatment effect of Mg is
mediated via lowering of BP or whether the BP effect is
simply 1 of the manifestations of Mg treatment is unclear.
The interaction between baseline BP and treatment was
present in both the efficacy population and the LACS subset.
Although the ISS groupings showed a clear relation with
outcome for the entire IMAGES population, the ISS has
limited discriminatory power within the LACS subgroup:
these patients mostly had ISS scores of 5 or below (upper
quartile). Interaction between ISS and Mg treatment was
identified neither in the efficacy dataset nor in the lacunar
subset. Because of small numbers in the lacunar group and
also the favorable prognosis of placebo-treated patients ow-
ing to a more benign natural history, our failure to demon-
strate any interaction between Mg treatment and ISS may not
be reliable. Our analysis is exploratory in nature and is not
powered to provide definitive results.
Identification of the Lacunar Population
The term “lacune” refers to pathoanatomic findings at au-
topsy.9 The computed tomography (CT)/magnetic resonance
imaging equivalent of a lacune is a small, deeply placed
infarct (SDI) and assumes that the imaged area of infarction
is within a territory of a single, perforating artery and presents
as small circular or oval changes approximately 1.5 cm in
diameter.9 Patients with lacunar stroke present mostly with 5
distinct stroke syndromes, collectively described as classic
lacunar syndromes. Classic lacunar syndromes include (1)
pure motor stroke, (2) sensorimotor stroke, (3) pure sensory
stroke, (4) dysarthria–clumsy hand syndrome, and (5) ataxic
hemiparesis. Lacunar stroke may thus be defined as a lacunar
syndrome combined with an SDI on imaging or with imaging
that is consistent with an SDI (ie, this may include a normal
CT scan). The method used for LACS classification in the
IMAGES trial included only pure motor stroke and sensori-
motor stroke.1 IMAGES required a single brain imaging
study within 7 days of stroke.
In IMAGES, a LACS classification was reasonably spe-
cific for the middle cerebral artery perforator infarction in
the efficacy population (70%) but had poor sensitivity
(43%).10 The imaging was consistent with LACS in 452
(59%) subjects: 186 middle cerebral artery perforator infarcts
(where the principal lesion was consistent with an acute
stroke), 38 atrophies only, and 228 normal scans. In sensitiv-
ity analysis, in those patients with a diagnosis that corre-
sponded to the definition of classic lacunar infarcts, the results
were entirely consistent with those in the main analysis. In
particular, the OR estimate for global outcome was similar to
Figure 2. LACS subgroup: treatment effect of Mg on outcome at 3 months. *Mg vs placebo, adjusted for stratification variables.
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that in the main sample, and the CI entirely covered the range
of CI in the original analysis (OR 0.75; 95% CI, 0.52 to 1.07,
adjusted for stratification variables; and OR 0.90, 95% CI,
0.48 to 1.70 in the full model). Unsurprisingly, as the sample
size was reduced substantially, the results were no longer
significant.
Further selection of ischemic lacunar stroke patients from
the LACS subgroup was done in sensitivity analysis only
because the majority of scans were performed after random-
ization. This may have biased the assessment of treatment
effect if Mg treatment caused the transformation of larger
strokes to lacunar. Additionally, anatomically plausible in-
farcts on delayed CT scans may not be causal, because CT
cannot discriminate reliably between acute and established
lesions.
In the European Cooperative Acute Stroke Study I trial of
tissue-type plasminogen activator treatment administered
within 4.21 hours of stroke onset, the predictive value,
sensitivity, specificity, and accuracy of clinical presentation
of lacunar stroke with pure motor stroke or sensorimotor
stroke was poor when compared with the standard of CT
assessment at 7 days.11 Similarly, baseline CT appearances of
leukoaraiosis and previous SDI had little value. Early CT
signs were also insensitive variables. The absence of early CT
signs combined with a pure motor stroke/sensorimotor stroke
presentation corresponded to lacunar infarct in 26% of
placebo and 33% of recombinant tissue-type plasminogen
activator patients.11 The study concluded that in the acute
setting of thrombolysis treatment, lacunar infarcts were not
recognizable on clinical and early CT grounds, either alone or
in combination.11
Diffusion-weighted imaging is the most sensitive and
specific imaging method for detection of subcortical ischemic
lesions during the acute phase of stroke.12 Diffusion-weighted
imaging, in conjunction with the apparent diffusion coeffi-
cient map, can differentiate between acute and nonacute
lesions. However, diffusion-weighted imaging was the rou-
tine acute imaging method at only very few centers world-
wide during the IMAGES recruitment period.
Future clinical trials should encourage the use of baseline
diffusion-weighted imaging to clarify the specific diagnostic
modalities that may benefit Mg treatment. Until universal
precise diagnosis is possible, a simple, reliable, clinical
method of selection of LACS is justified because of data
availability, clinical assessment before randomization, and
the low accuracy of early CT assessment. Within this group,
a benefit of Mg treatment on outcome remains a possibility.
In conclusion, this further analysis of the IMAGES data
suggests that the positive interaction between Mg and LACS
cannot be ascribed to confounding issues of severity, time
to treatment, BP, or other baseline factors. A trial of Mg
treatment in acute LACS is justified and necessary to confirm
these results.
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